MedTrace Logo

COPD Exacerbation Blood and Urine Biomarkers Study

NCT03823443 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2024-06-04

No results posted yet for this study

Summary

This will be a prospective study examining serum levels of MMP-13 and alpha-1 antitrypsin as well as other biomarkers as well as urine biomarkers of smoking status and collagen degradation in the COPD patient population. Serum and urine biomarkers at baseline and after COPD exacerbations will be assessed against change in lung function as measured by pulmonary function testing.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Monica Goldklang, MD · Columbia University

Eligibility

Min Age
35 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-07
Primary Completion
2019-08-22
Completion
2021-01-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03823443 on ClinicalTrials.gov